Active Ingredient(s): Caplacizumab-yhdp
FDA Approved: * February 6, 2019
Pharm Company: * ABLYNX NV
Category: Blood Clotting (Hemostasis)

Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.[2][3][4][5] This drug was developed by Ablynx NV.[6] On 30 August 2018, it was approved in the European Union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchang... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

CabliviCablivi Intravenous; Subcutaneous Kit
NDC: 58468-0225
Genzyme Corporation